The montreal cognitive assessment: short cognitive evaluation in a large stroke trial.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 21757673.
- Also identified by DOI 10.1161/STROKEAHA.111.619486.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cognitive function is often ignored in stroke research trials. The brief Montreal Cognitive Assessment (MoCA) may be sensitive to stroke-related cognitive deficits. We evaluated the feasibility of administering the MoCA at 3 months in a large stroke trial (A Very Early Rehabilitation Trial [AVERT]). Data (blinded to intervention group) are presented for 294 patients with mean age of 70.6 years (SD, 12.8); 220 (75%) completed the MoCA, 54 (18%) had missing data, and 20 (7%) had died. Of those surviving to 3 months, the MoCA was completed by 87% with mild stroke, 79% with moderate stroke, and 67% with severe stroke on admission. Mean MoCA score was 21.1 (SD 7.5) out of 30; only 78 of 220 (35%) patients attained the "normal" cutoff (≥26). The MoCA is a feasible global cognitive screening tool in stroke trials. Clinical Trial Registration- URL: www.anzctr.org.au/trial_view.aspx?ID=1266. Unique identifier: ACTRN12606000185561.
Medical subject headings
- Cognition
- Stroke